Dong-Kyu Kim

The sphenoid sinus presents significant challenges during endoscopic sinus surgery. It is essential that surgeons employ strategies that effectively address sphenoid pathology while minimizing surgical risks and optimizing outcomes. Although nomenclature for maxillary and frontal sinus surgery is well established, there is currently no standardized nomenclature for sphenoid sinus surgery. We present a comprehensive review of techniques for accessing the sphenoid sinus and propose a common surgical classification system to better define and categorize these approaches. Each technique is classified based on surgical extent, anticipated operation time, complexity, potential complications, and expected wound healing, aligning with established standards in the literature. The proposed sphenoidotomy types are as follows: type I, sphenoid ostial dilation; type IIa, transnasal sphenoidotomy (sphenoidotomy without ethmoidectomy); type IIb, transethmoidal sphenoidotomy (sphenoidotomy with ethmoidectomy); type III, bilateral, common cavity sphenoidotomy, or “sphenoid drill-out;” type IV, transpterygoid approach, to expose the lateral sphenoid sinus recess; and type V, sphenoid nasalization, completely removing the sphenoid sinus floor. By standardizing the nomenclature for these techniques, we aim to enhance consistency in terminology for teaching, surgical planning, clinical research, and interdisciplinary communication in sphenoid sinus surgery.

Hospital sleep medicine is a burgeoning field that underscores the critical role of sleep in the recovery and overall health of hospitalized patients. Hospitalized patients often suffer from sleep disturbances due to environmental disruptions, medical interventions, and underlying illnesses, each of which can impede healing and extend recovery times. This problem is compounded by multi-patient hospital rooms, frequent nighttime disturbances, and a general lack of focus on sleep management within institutions. Furthermore, many hospitalized patients have undiagnosed sleep disorders such as obstructive sleep apnea (OSA) and insomnia, which can further compromise immune function, increase postoperative complications, and exacerbate cognitive and emotional distress. Integrating sleep assessments and targeted interventions into hospital care promises to improve patient outcomes, accelerate recovery, and reduce healthcare costs. Efficient strategies include early identification and management of sleep disorders, using treatments such as continuous positive airway pressure for OSA, and cognitive behavioral therapy for insomnia. Nonetheless, awareness among healthcare providers is still insufficient, leading to the underutilization of screening and interventions for sleep disorders. This review emphasizes the necessity for systematic sleep evaluations, education for healthcare providers, and the development of customized sleep management strategies. Special consideration should be given to vulnerable populations, including surgical and cancer patients, individuals with psychiatric or neurological disorders, and pediatric inpatients. The integration of hospital sleep medicine into routine clinical practice is crucial for enhancing patient recovery, overall safety, and healthcare quality. A systemic shift towards prioritizing sleep in hospital settings is essential to ensure that sleep medicine becomes a fundamental component of comprehensive patient care.

Background/Objectives: We investigated the association between chronic rhinosinusitis (CRS) and cancer risk in an adult Korean population. Methods: This retrospective cohort study used data from the Korean National Health Insurance Service database. To ensure comparability between the groups, adjustments were made for potential confounding factors, including sex, age, residence, household income, diabetes, hypertension, and chronic kidney disease. The primary endpoint was the presence of newly diagnosed cancer. Results: Among 1,337,120 individuals in the nationally representative cohort database, 10,567 patients with CRS were identified and matched with 42,268 control subjects without CRS. Patients with CRS had a significantly higher risk of overall cancer events than controls. The adjusted hazard ratio (HR) for cancer in the CRS group was 1.16 (95% confidence interval [CI]: 1.05–1.28). Notably, female patients with CRS had an elevated risk of incident cancer events. Furthermore, patients with CRS without nasal polyps exhibited a significantly increased risk of cancer, whereas those with CRS with nasal polyps did not show a similar association. Conclusions: These findings underscore the need for physicians to carefully monitor patients with CRS for potential cancer progression and develop appropriate therapeutic strategies to mitigate the impact of this condition.

Background/Objectives: One prior study revealed that a newly developed auto-titrating mandibular advancement device (AMAD) could potentially enhance polysomnographic outcomes in individuals with obstructive sleep apnea (OSA). However, evidence regarding its impact on autonomic nervous system dysregulation in OSA remains limited. In this study, we aimed to compare the effects of conventional mandibular advancement devices (MADs) and AMDA on autonomic function. Methods: We retrospectively reviewed data from patients who visited a sleep center with complaints of snoring and sleep apnea (30 and 15 patients in the conventional MAD and AMAD groups, respectively). We assessed heart rate variability (HRV) frequency-domain metrics such as total power (TP), very low frequency (VLF), low frequency (LF), and high frequency (HF) using ultra-short-term and short-term modalities, assessing sympathetic and parasympathetic activity changes across treatment groups. Results: Conventional MAD treatment was associated with reductions in LF and LF/HF ratios, whereas AMAD treatment was linked to decreases in TP, VLF, LF, and LF/HF ratios. Notably, in patients with moderate OSA, LF values were significantly lower in the AMAD group than in the conventional MAD group. Conclusions: These findings suggest that both devices could reduce sympathetic over-activity in patients with OSA, with AMAD demonstrating greater efficacy, particularly in those with moderate OSA.

Background and Objectives: The medications preferred by patients for allergic rhinitis and their usage remain unclear. This study investigated treatment-seeking behaviors in patients with allergic rhinitis, including medical treatments, environmental controls, and surgical treatments.Methods: In this study, a cross-sectional survey was conducted by internal medicine, pediatric, or otorhinolaryngology physicians at university hospitals from January 2022 to April 2022. A questionnaire was administered to patients with confirmed allergic rhinitis to collect information regarding medical treatments (prescription and over-the-counter medication use patterns, comorbid asthma, and allergen-specific immunotherapy), environmental controls (usage of air purifiers and pet avoidance), and experiences with surgical treatments.Results: We included 51 patients with allergic rhinitis with a mean age of 31.6±16.0 years. Among them, 47 (92.2%) and 6 (11.8%) patients had pollen allergies and asthma, respectively. Furthermore, 41 (80.4%) patients took prescribed medicines, while 39 (76.5%) patients only used the medication when experiencing symptoms. Thirty patients (58.8%) reported concurrent use of intranasal sprays and oral medications. Thirty-three patients (64.7%) reported awareness of immunotherapy, and there were no preferential differences between subcutaneous (52%) and sublingual immunotherapy (48%). Of the 36 patients (70.6%) who reported using an air purifier, 38.9% considered it helpful in preventing allergic rhinitis symptoms. Fourteen patients (27.5%) currently or previously had a companion animal, with half experiencing worsening of symptoms. Twelve patients had received surgical treatment and reported high satisfaction levels (41.6%, very satisfied; 41.6%, satisfied).Conclusion: Patients with allergic rhinitis showed similar preferences for oral and spray medications. They also showed satisfaction with surgical treatments and an interest in the environmental management of allergic rhinitis.

Objectives. Although mandibular advancement device (MAD) treatment is effective for obstructive sleep apnea (OSA), some concerns remain regarding its potential therapeutic impact and side effects. Thus, we developed a novel MAD that auto-titrates depending on its position in patients with OSA. We conducted a clinical trial to determine the efficacy of an auto-titrating mandibular advancement device (AMAD) for treating OSA.Methods. Fourteen patients diagnosed with OSA participated in this study. Polysomnography (PSG) was performed at the beginning of the clinical trial, and after 3 months of treatment, PSG with AMAD in situ was conducted.Results. The mean scores for the Epworth Sleepiness Scale (ESS) and STOP-Bang were 8.21±4.21 and 5.00±1.00, respectively. After 3 months of AMAD treatment, the STOP-Bang scores improved to 3.75±1.06; however, the ESS scores did not show a significant change. Additionally, we observed statistically significant improvements in several respiratory parameters in the PSG data following AMAD treatment. These included reductions in the apnea-hypopnea index (AHI) (from 32.85±21.71 to 12.93±10.70), supine AHI (from 45.91±23.58 to 15.59±12.76), and lateral AHI (from 13.94±10.95 to 5.49±7.40). Improvements were also noted in the lowest O2 saturation (from 79.71±6.22 to 84.00± 5.71), total arousal number (from 191.14±112.07 to 86.57±48.80), and arousal index (from 33.76±21.00 to 15.05± 8.42). However, there were no significant changes in total sleep time, sleep efficiency, or mean oxygen saturation. Additionally, no major side effects were observed during treatment, specifically related to tooth or jaw pain.Conclusion. Our clinical trial found that AMAD improved PSG parameters and reduced the incidence of common side effects. Therefore, AMAD may be an effective alternative treatment for OSA.

Background/Objectives: Numerous studies have explored the association between chronic rhinosinusitis (CRS) and cognitive decline. However, whether CRS is an independent risk factor for the development of dementia remains unclear. Thus, this retrospective cohort study sought to examine the potential association between CRS and increased incidence and risk of dementia by utilizing a representative population-based cohort dataset. Methods: In this study, we identified 2126 patients with CRS aged >55 years and matched them with 8504 controls to assess the incidence and risk of dementia. Results: We found that the incidence of all-cause dementia in CRS patients was 0.125 per 1000 person-years. The risk of developing all-cause dementia events (adjusted hazard ratio [HR] = 1.0, 95% confidence interval = 0.8–1.3) also did not differ significantly between the control group and the CRS group, irrespective of the CRS phenotype. Subgroup analysis also showed no increased adjusted HR for developing Alzheimer’s disease (0.9, 0.7–1.2), Parkinson’s disease (0.9, 0.5–1.4), and other types of dementia (1.0, 0.7–1.4) in the CRS group compared to the control group. Conclusions: Therefore, the present study demonstrated that patients over 55 years of age with CRS did not exhibit an increased incidence or risk of dementia compared to individuals without CRS.

Objectives. Sinonasal squamous cell carcinoma (SqCC) often invades the orbit. The treatment approach for sinonasal cancer that has spread to the orbit varies across medical centers and depends on the extent of the invasion. The decision to preserve the orbit in the treatment strategy is made on a case-by-case basis and results in varying outcomes. Currently, a multimodal treatment regimen, which may include surgery, chemotherapy, radiotherapy (RT), or concurrent chemoradiotherapy (CCRT), is commonly adopted for managing sinonasal cancers. This study aims to assess the prognosis of sinonasal SqCC with orbital invasion from various perspectives.Methods. We conducted a retrospective review of patients with primary sinonasal SqCC invading the orbit who were treated at Seoul National University Hospital and Seoul National University Bundang Hospital between 2009 and 2018. The extent of the tumor, orbital invasion, treatment strategies, recurrence rates, and survival rates were analyzed.Results. Overall survival and disease-free survival (DFS) rates showed no significant differences based on the grade of orbital invasion. When tumor resection with orbit preservation was employed as the definitive treatment, DFS was significantly extended compared to cases where surgery was not the definitive treatment (RT or CCRT). Additionally, there was no significant difference in DFS between patients who underwent orbit exenteration and those who underwent tumor resection with orbit preservation as the definitive treatment.Conclusion. Tumor resection with orbit preservation as the definitive treatment appears to be the preferred approach, prolonging DFS and increasing the likelihood of longer-term survival in cases of SqCC with orbital invasion.

Background: The effectiveness of aspirin for the primary prevention of cerebro-cardiovascular diseases in Koreans remains unclear. Therefore, we evaluated the preventive effects of low-dose aspirin (equal or less than 100 mg) on cerebro-cardiovascular events. Method: We conducted a retrospective cohort study using the National Sample Cohort dataset. From the 1,106,580 individuals eligible in 2004, we selected 200 individuals (47% male and 22.5% aged 65 or older) who consistently received low-dose aspirin from 2004 to 2013 for inclusion in the aspirin cohort. Participants for the control cohort, who did not use aspirin, were selected through propensity score matching based on variables. Result: We compared the incidences of endpoints (acute myocardial infarction, cerebral infarction, gastrointestinal hemorrhage, and cerebral hemorrhage) between the aspirin group and the non-aspirin group over the 9-year follow-up period. There was no significant difference in the incidence rates of acute myocardial infarction, cerebral infarction, gastrointestinal hemorrhage, or cerebral hemorrhage between the aspirin and non-aspirin groups. Low-dose aspirin for primary prevention in Koreans did not reduce myocardial or cerebral infarctions and did not increase the risk of gastrointestinal or cerebral hemorrhage. Conclusion: Therefore, we suggest that aspirin for primary prevention should be used cautiously and tailored to the individual’s baseline cardiovascular risk.

Head and neck cancers (HNC) are frequently associated with neurodegeneration. However, the association between HNC and Parkinson’s disease (PD) remains unclear. This study aimed to clarify the relationship between HNC and subsequent PD. This retrospective study used data from a nationally representative cohort. Patients with HNC were identified based on the presence of corresponding diagnostic codes. Participants without cancer were selected using 4:1 propensity score matching based on sociodemographic factors and year of enrollment; 2296 individuals without HNC and 574 individuals with HNC were included in the study. Hazard ratios (HR) for the incidence of PD in patients with HNC were calculated using 95% confidence intervals (CI). The incidence of PD was 4.17 and 2.18 per 1000 person-years in the HNC and control groups, respectively (adjusted HR = 1.89, 95% CI = 1.08–3.33). The HNC group also showed an increased risk of subsequent PD development. The risk of PD was higher in middle-aged (55–69 years) patients with HNC and oral cavity cancer. Our findings suggest that middle-aged patients with HNC have an increased incidence of PD, specifically those with oral cavity cancer. Therefore, our findings provide new insights into the development of PD in patients with HNC.